WO2025169059 - INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
National phase entry is expected:
Publication Number
WO/2025/169059
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051155
International Filing Date
03.02.2025
Title **
[English]
INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
[French]
INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
Applicants **
VIIV HEALTHCARE UK (NO.5) LIMITED
Inventors
PATEL, Manoj
GILLIS, Eric P
BOWSHER, Michael S.
IWUAGWU, Christiana
PARCELLA, Kyle E.
NAIDU, B Narasimhulu
Priority Data
63/549,602
05.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 9971 | |
| EPO | Filing, Examination, Granting | 59637 | |
| Japan | Filing, Examination, Granting | 3662 | |
| South Korea | Filing, Examination, Granting | 5015 | |
| USA | Filing, Examination, Granting | 31340 |
Total:
109,625
Contact Us
Abstract[English]
A compound of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treatment or prevention of human immunodeficiency virus (HIV) infection are set forth: Formula (I).[French]
L'invention concerne un composé de formule (I), ainsi que des sels pharmaceutiquement acceptables de celui-ci, et des compositions et des méthodes de traitement ou de prévention d'une infection par le virus de l'immunodéficience humaine (VIH). Formule (I).